These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 20002104)

  • 1. Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist.
    Cascio MG; Gauson LA; Stevenson LA; Ross RA; Pertwee RG
    Br J Pharmacol; 2010 Jan; 159(1):129-41. PubMed ID: 20002104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.
    Thomas A; Stevenson LA; Wease KN; Price MR; Baillie G; Ross RA; Pertwee RG
    Br J Pharmacol; 2005 Dec; 146(7):917-26. PubMed ID: 16205722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.
    Pertwee RG; Thomas A; Stevenson LA; Ross RA; Varvel SA; Lichtman AH; Martin BR; Razdan RK
    Br J Pharmacol; 2007 Mar; 150(5):586-94. PubMed ID: 17245367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties.
    Pertwee RG; Gibson TM; Stevenson LA; Ross RA; Banner WK; Saha B; Razdan RK; Martin BR
    Br J Pharmacol; 2000 Apr; 129(8):1577-84. PubMed ID: 10780961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
    Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
    Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.
    Thomas A; Baillie GL; Phillips AM; Razdan RK; Ross RA; Pertwee RG
    Br J Pharmacol; 2007 Mar; 150(5):613-23. PubMed ID: 17245363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice.
    Bolognini D; Costa B; Maione S; Comelli F; Marini P; Di Marzo V; Parolaro D; Ross RA; Gauson LA; Cascio MG; Pertwee RG
    Br J Pharmacol; 2010 Jun; 160(3):677-87. PubMed ID: 20590571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
    Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
    Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo profiling of fadolmidine, a novel potent alpha(2)-adrenoceptor agonist with local mode of action.
    Lehtimäki J; Leino T; Koivisto A; Viitamaa T; Lehtimäki T; Haapalinna A; Kuokkanen K; Virtanen R
    Eur J Pharmacol; 2008 Dec; 599(1-3):65-71. PubMed ID: 18930723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bioassay of cannabinoids using the mouse isolated vas deferens.
    Thomas A; Pertwee RG
    Methods Mol Med; 2006; 123():191-207. PubMed ID: 16506409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens.
    Pertwee RG; Ross RA; Craib SJ; Thomas A
    Eur J Pharmacol; 2002 Dec; 456(1-3):99-106. PubMed ID: 12450575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that (-)-7-hydroxy-4'-dimethylheptyl-cannabidiol activates a non-CB(1), non-CB(2), non-TRPV1 target in the mouse vas deferens.
    Pertwee RG; Thomas A; Stevenson LA; Maor Y; Mechoulam R
    Neuropharmacology; 2005 Jun; 48(8):1139-46. PubMed ID: 15910889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist.
    Thomas A; Ross RA; Saha B; Mahadevan A; Razdan RK; Pertwee RG
    Eur J Pharmacol; 2004 Mar; 487(1-3):213-21. PubMed ID: 15033394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands.
    Cascio MG; Bisogno T; Palazzo E; Thomas A; van der Stelt M; Brizzi A; de Novellis V; Marabese I; Ross R; van de Doelen T; Brizzi V; Pertwee R; Maione S; Di Marzo V
    Br J Pharmacol; 2006 Oct; 149(4):431-40. PubMed ID: 16953186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for a functional alpha 1A- (alpha 1C-) adrenoceptor mediating contraction of the rat epididymal vas deferens and an alpha 1B-adrenoceptor mediating contraction of the rat spleen.
    Burt RP; Chapple CR; Marshall I
    Br J Pharmacol; 1995 Jun; 115(3):467-75. PubMed ID: 7582458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse.
    Lay L; Angus JA; Wright CE
    Eur J Pharmacol; 2000 Mar; 391(1-2):151-61. PubMed ID: 10720647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor.
    Bolognini D; Cascio MG; Parolaro D; Pertwee RG
    Br J Pharmacol; 2012 Apr; 165(8):2561-74. PubMed ID: 21615724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel selective cannabinoid CB(1) receptor antagonist MJ08 with potent in vivo bioactivity and inverse agonistic effects.
    Chen W; Xu C; Liu HY; Long L; Zhang W; Zheng ZB; Xie YD; Wang LL; Li S
    Acta Pharmacol Sin; 2011 Sep; 32(9):1148-58. PubMed ID: 21841814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Δ8-Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors.
    Bátkai S; Mukhopadhyay P; Horváth B; Rajesh M; Gao RY; Mahadevan A; Amere M; Battista N; Lichtman AH; Gauson LA; Maccarrone M; Pertwee RG; Pacher P
    Br J Pharmacol; 2012 Apr; 165(8):2450-61. PubMed ID: 21470208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1).
    Hillard CJ; Manna S; Greenberg MJ; DiCamelli R; Ross RA; Stevenson LA; Murphy V; Pertwee RG; Campbell WB
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1427-33. PubMed ID: 10336536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.